Drug Trial Radar · NCT00449176
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
Last checked: Nov 19, 2026Latest source record: Apr 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
981
Actual
Start
Feb 2007
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Grünenthal GmbH
- First posted
- Mar 20, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain of the lower back, in comparison with placebo and Oxycodone Controlled Release (CR).
Conditions
- Low Back Pain
Interventions
tapentadol (CG5503) ERDrug
50, 100, 150, 200, 250 mg twice daily for 15 weeks
oxycodone CRDrug
10, 20, 30, 40, 50 mg twice daily for 15 weeks
placeboDrug
matching placebo twice daily for 15 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.Time frame: Baseline and 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.